-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IL0BhfIoCNtICg9Uno07gDM8CNdy+U8mxBYs4Ax6JlqpWRSlnGG1eiG+N+TZtdE9 /s92/rYlZJ7Om0EGvGhZEQ== 0001230295-06-000319.txt : 20061212 0001230295-06-000319.hdr.sgml : 20061212 20061212190344 ACCESSION NUMBER: 0001230295-06-000319 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061208 FILED AS OF DATE: 20061212 DATE AS OF CHANGE: 20061212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CLEMENT CHRISTOPHER G CENTRAL INDEX KEY: 0001218808 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 061272666 MAIL ADDRESS: STREET 1: C/O BIOTECHNOLOGY GENERAL CORP STREET 2: ONE TOWER CENTER BLVD 14TH FLR CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 4 1 cle123.xml X0202 4 2006-12-08 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001218808 CLEMENT CHRISTOPHER G C/O SAVIENT PHARMACEUTICALS, INC. ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 0 1 0 0 President & CEO Common Stock, $.01 par value per share 2006-12-08 4 A 0 65000 A 211140.0000 D Option to Purchase Common Stock, $0.01 par value 12.1100 2006-12-08 4 A 0 195000 0 A 2007-12-08 2016-12-08 Common Stock, $.01 par value per share 195000.0000 195000.0000 D The right to receive these shares is pursuant to a restricted stock grant and such shares issue and vest as to 33.3% each on 12/8/07, 12/8/08 and 12/8/09, provided the grantee remains employed by the Company on these dates. These options will become exercisable as to 25% on each 12/8/07,12/8/08, 12/8/09 and 12/8/10, provided the optionee remains employed by the Company on these dates. By: Michelle Zelinski as Attorney-In-Fact for 2006-12-12 -----END PRIVACY-ENHANCED MESSAGE-----